NEUROLOGIE PRO PRAXI / Neurol. Praxi. 2024;25(3):231-238 / www.neurologiepropraxi.cz 238 Z POMEZÍ NEUROLOGIE Spastická paraparéza jako klinická manifestace závažné X‑vázané adrenoleukodystrofie LITERATURA 1. Bezman L, Moser AB, Raymond GV, et al. Adrenoleukody‑ strophy: incidence, new mutation rate, and results of exten‑ ded family screening. Ann Neurol. 2001;49:512-517. 2. Blevins LS, Jr., Shankroff J, Moser HW, et al. Elevated plas‑ ma adrenocorticotropin concentration as evidence of limited adrenocortical reserve in patients with adrenomyeloneuro‑ pathy. J Clin Endocrinol Metab. 1994;78:261-265. 3. Di Rocco M, Doria‑Lamba L, Caruso U. Monozygotic twins with X‑linked adrenoleukodystrophy and different phenoty‑ pes. Ann Neurol. 2001;50:424. 4. Dubey P, Raymond GV, Moser AB, et al. Adrenal insuffi‑ ciency in asymptomatic adrenoleukodystrophy patients identified by very long‑chain fatty acid screening. J Pediatr. 2005;146:528-532. 5. Dvorakova L, Hrebicek M, Jahnova H, et al. X‑linked adreno‑ leukodystrophy in twenty one Czech patients. Ces‑slov Pediatr. 2006;61(3):129-136. 6. Eichler F, Duncan C, Musolino PL, et al. Hematopoietic Stem ‑Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017;377:1630-1638. 7. Engelen M, Barbier M, Dijkstra IM, et al. X‑linked adrenole‑ ukodystrophy in women: a cross‑sectional cohort study. Brain. 2014;137:693-706. 8. Engelen M, Kemp S, de Visser M, et al. X‑linked adrenoleukody‑ strophy (X‑ALD): clinical presentation and guidelines for diagno‑ sis, follow‑up and management. Orphanet J Rare, DiS. 2012;7:51 9. Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X‑linked adrenoleukodystrophy. N Engl J Med. 2010;362:276-277. 10. Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Pa‑ tients With Adrenoleukodystrophy: A Consensus‑Based Appro‑ ach. Neurology. 2022;99:940-951. 11. Fanen P, Guidoux S, Sarde CO, et al. Identification of muta‑ tions in the putative ATP‑binding domain of the adrenoleuko‑ dystrophy gene. J Clin Invest. 1994;94:516-520. 12. Fatemi A, Barker PB, Ulug AM, et al. MRI and proton MRSI in women heterozygous for X‑linked adrenoleukodystrophy. Neurology. 2003;60:1301-1307 13. Fourcade S, Lopez‑Erauskin J, Galino J, et al. Early oxidative damage underlying neurodegeneration in X‑adrenoleukody‑ strophy. Hum Mol Genet. 2008;17:1762-1773. 14. Guettsches AK, Kuechler A, Gal A, et al. Female carriers of X ‑chromosomal adrenoleukodystrophy: a major differential dia‑ gnosis in progressive myelopathy. J Neurol. 2010;257:1394-1395. 15. Hershkovitz E, Narkis G, Shorer Z, et al. Cerebral X‑linked adre‑ noleukodystrophy in a girl with Xq27-Ter deletion. Ann Neurol. 2002;52:234-237. 16. Huffnagel IC, Dijkgraaf MGW, Janssens GE, et al. Disease pro‑ gression in women with X‑linked adrenoleukodystrophy is slow. Orphanet J Rare, DiS. 2019;14:30. 17. Huffnagel IC, Laheji FK, Aziz‑Bose R, et al. The Natural His‑ tory of Adrenal Insufficiency in X‑Linked Adrenoleukodystro‑ phy: An International Collaboration. J Clin Endocrinol Metab. 2019;104:118-126. 18. Huffnagel IC, van de Beek MC, Showers AL, et al. Compa‑ rison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy. Mol Genet Metab. 2017;122:209-215. 19. Jaspers YRJ, Ferdinandusse S, Dijkstra IME, et al. Comparison of the Diagnostic Performance of C26:0-Lysophosphatidylcho‑ line and Very Long‑Chain Fatty Acids Analysis for Peroxisomal Disorders. Front Cell Dev Biol. 2020;8:690. 20. Keam SJ. Elivaldogene Autotemcel: First Approval. Mol Diagn Ther. 2021;25:803-809. 21. Kemp S, Berger J, Aubourg P. X‑linked adrenoleukodystro‑ phy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta. 2012;1822:1465-1474. 22. Kemp S, Huffnagel IC, Linthorst GE, et al. Adrenoleukodystro‑ phy - neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol. 2016;12:606-615. 23. Kemp S, Pujol A, Waterham HR, et al. ABCD1 mutations and the X‑linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001;18:499-515. 24. Korenke GC, Fuchs S, Krasemann E, et al. Cerebral adrenole‑ ukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann Neurol. 1996;40:254-257. 25. Krasemann EW, Meier V, Korenke GC, et al. Identification of mutations in the ALD‑gene of 20 families with adrenoleukody‑ strophy/adrenomyeloneuropathy. Hum Genet. 1996;97:194-197. 26. Lauer A, Da X, Hansen MB, et al. ABCD1 dysfunction alters white matter microvascular perfusion. Brain. 2017;140:3139-3152. 27. Loes DJ, Hite S, Moser H, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15:1761-1766. 28. Mahmood A, Dubey P, Moser HW, et al. X‑linked adrenoleu‑ kodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant. 2005;9(Suppl. 7):55-62. 29. Mahmood A, Raymond GV, Dubey P, et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X‑linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6:687-692. 30. Monternier PA, Singh J, Parasar P, et al. Therapeutic poten‑ tial of deuterium‑stabilized (R)-pioglitazone‑PXL065-for X‑lin‑ ked adrenoleukodystrophy. J Inherit Metab, DiS. 2022;45:832-847. 31. Moser AB, Kreiter N, Bezman L, et al. Plasma very long cha‑ in fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45:100-110. 32. Moser HW, Mahmood A, Raymond GV. X‑linked adrenoleu‑ kodystrophy. Nat Clin Pract Neurol. 2007;3:140-151. 33. Moser HW, Raymond GV, Dubey P. Adrenoleukodystro‑ phy: new approaches to a neurodegenerative disease. JAMA. 2005;294:3131-3134. 34. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single‑institution cohort report. Blood. 2011;118:1971-1978. 35. Peters C, Charnas LR, Tan Y, et al. Cerebral X‑linked adrenole‑ ukodystrophy: the international hematopoietic cell transplan‑ tation experience from 1982 to 1999. Blood. 2004;104:881-888. 36. Powers JM, Liu Y, Moser AB, et al. The inflammatory mye‑ linopathy of adreno‑leukodystrophy: cells, effector mole‑ cules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992;51:630-643. 37. Powers JM, Schaumberg HH. Adreno‑leukodystrophy. Simi‑ lar ultrastructural changes in adrenal cortical and Schwann ce‑ lls. Arch Neurol. 1974;30:406-408. 38. Raymond GV, Aubourg P, Paker A, et al. Survival and Func‑ tional Outcomes in Boys with Cerebral Adrenoleukodystrophy with and without Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25:538-548. 39. Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther. 2007;11:381-384. 40. Turk BR, Theda C, Fatemi A, et al. X‑linked adrenole‑ ukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80:52-72. 41. van de Stadt SIW, Huffnagel IC, Turk BR, et al. Ima‑ ging in X‑Linked Adrenoleukodystrophy. Neuropediatrics. 2021;52:252-260. 42. van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X‑linked adreno‑ leukodystrophy. Ann Neurol. 2001;49:186-194. 43. van Geel BM, Koelman JH, Barth PG, et al. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology. 1996; 46: 112-118 44. Wanders RJ. Metabolic functions of peroxisomes in health and disease. Biochimie. 2014;98:36-44. 45. Wang Y, Busin R, Reeves C, et al. X‑linked adrenoleu‑ kodystrophy: ABCD1 de novo mutations and mosaicism. Mol Genet Metab. 2011;104:160-166. 46. Zemanova M, Chrastina P, Dvorakova L, et al. X‑linked adrenoleukodystrophy: phenotype‑genotype correlati‑ on in hemizygous males and heterozygous females with ABCD1 mutations. Neuro Endocrinol Lett. 2021;42:359-367. 47. Zolman BK, Silva ID, Bartel B. The Arabidopsis pxa1 mutant is defective in an ATP‑binding cassette transporter ‑like protein required for peroxisomal fatty acid beta ‑oxidation. Plant Physiol. 2001;127:1266-1278. KNIŽNÍ NOVINKA PACIENT A ZDRAVOTNICKÝ PRACOVNÍK ŘEŠENÍ KONFLIKTNÍCH SITUACÍ Auzká Erika Kniha se zabývá problematikou jednání zdravotnických pracovníků vůči pacientům a jejich rodinným příslušníkům. Na příkladech se autorka snaží přiblížit situace, které běžně ve zdravotnictví nastávají a komplikují pacientům život či dokonce mohou pacienta poškodit. Závěrem každého případu je poučení pro čtenáře, jak by měli ideálně v obdobných situacích jednat. Autorka vychází ze svých zkušeností dlouholetého pracovníka ve zdravotnictví a ze zkušeností, kterých nabyla v životě jako pacient‑ ka či rodinný příslušník pacienta. Zároveň čtenářům přibližuje některá témata související s činností zdravotnických zařízení, o kterých se zpravidla zásadně veřejně nehovoří. Ačkoliv je většina kapitol smutným obrazem českého zdravotnictví, má kniha za cíl povzbudit čtenáře, že svým aktivním postojem dokážou lépe čelit všemu, co může v jejich životech při komunikaci se zdravotníky nastat.
RkJQdWJsaXNoZXIy NDA4Mjc=